SanBio Co Ltd
4592
Company Profile
Business description
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Contact
8-1 Street Luke Tower 32nd Floor
Akashi-cho, Chuo-ku
Tokyo104-0044
JPNT: +81 362643481
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 January 2026
Employees
29
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.80 | 12.90 | 0.15% |
| CAC 40 | 7,848.23 | 60.13 | 0.77% |
| DAX 40 | 24,140.14 | 101.95 | 0.42% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,725.87 | 0.14 | -0.00% |
| HKSE | 23,573.38 | 315.07 | 1.35% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
| NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
| SSE Composite Index | 3,363.45 | 23.51 | 0.70% |